ARK Genomic Revolution ETF (ARKG)
| Assets | $2.37B |
| Expense Ratio | 0.75% |
| PE Ratio | 27.58 |
| Forward PE | 24.43 |
| Shares Out | 43.55M |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| Volume | 10,940,713 |
| Open | 53.09 |
| Previous Close | 55.11 |
| Day's Range | 50.25 - 54.00 |
| 52-Week Low | 24.60 |
| 52-Week High | 58.83 |
| Beta | 1.73 |
| Holdings | 35 |
| Inception Date | Oct 31, 2014 |
About ARKG
Fund Home PageThe ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is issued by ARK.
Top 10 Holdings
58.52% of assets| Name | Symbol | Weight |
|---|---|---|
| Twist Bioscience Corporation | TWST | 8.74% |
| 10x Genomics, Inc. | TXG | 8.72% |
| Tempus AI, Inc. | TEM | 8.36% |
| Absci Corporation | ABSI | 5.55% |
| CRISPR Therapeutics AG | CRSP | 5.22% |
| Guardant Health, Inc. | GH | 4.88% |
| Natera, Inc. | NTRA | 4.71% |
| Illumina, Inc. | ILMN | 4.69% |
| Eli Lilly and Company | LLY | 3.92% |
| Beam Therapeutics Inc. | BEAM | 3.73% |
Performance
ARKG had a total return of 71.51% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.79%.
News
Beyond Cellular Models: Longevica Capitalizes on World's Largest In Vivo Longevity Study to Form Star-Studded Advisory Board and Unlock Human Health-and-Lifespan Pipeline
SAN FRANCISCO & NEW YORK--(BUSINESS WIRE)---- $ARKG #AI--Longevica forms a star SAB to turn its $13M, 16k-subject mammalian study into AI-driven drug discovery, pet health, and novel human therapies.
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track...
Cathie Wood on DeepSeek, Nvidia, Stock Picks, China, AI
Chinese AI startup DeepSeek has released a new open-source AI model called R1 that can mimic human reasoning, rivalling or outperforming leading US developers on industry benchmarks. The release of R1...
BMO Transfers 3 BMO Mutual Fund ETF Series, Managed by ARK Investment Management, to Cboe Canada
TORONTO--(BUSINESS WIRE)---- $ARKG #Cboe--Cboe Canada is pleased to announce BMO has transferred three BMO mutual fund ETF series, trading under the symbols ARKK, ARKW, and ARKG to Cboe Canada.
Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April
Hello! This week's ETF Wrap digs into the slump in ETF flows in April and investor positioning around commodities as inflation worries persist.
China-focused ETFs struggle amid fears of another regulatory ‘crackdown'
Hi! This week's ETF Wrap funds looks at China-focused funds that are struggling in 2024, with Clocktower's chief strategist Marko Papic providing his take on concerns tied to the country.
How to Find the Best Biotech ETFs
The best biotech ETFs allow investors a diversified way to play the volatile biotechnology industry. Here's how to find them.
Cathie Wood Says ARK Funds Are Seeing Flows Coming Back
ARK Invest CEO and CIO Cathie Wood comments on ARK's fund flows during an interview with Romaine Bostick and Katie Greifeld on "Bloomberg Markets: The Close."